- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05971251
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
Addition of loNcasTuxImab teSirine to AcalabruTinib in Chronic Lymphocytic Leukemia(Anti-Static Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a phase I study which will employ the Bayesian optimal interval (BOIN) design to find the maximum tolerated dose (MTD).
Approximately 24 Dose-Limiting Toxicity (DLT) evaluable participants will be treated to find MTD with a target DLT rate of 25%, and 4 pre-specified doses. The total number of participants enrolled will depend on the frequency of DLTs and when the MTD is determined. The maximum number of patients at a given dose level is 12.
The dose of acalabrutinib will be fixed and loncastuximab tesirine will be titrated as in dose level table 1 below.
Table 1. Dose levels Dose Level Schedule
- 45 µg/kg Loncastuximab Tesirine + Acalabrutinib 100 mg BID
- 60 µg/kg Loncastuximab Tesirine + Acalabrutinib 100 mg BID
- 75 µg/kg Loncastuximab Tesirine + Acalabrutinib 100 mg BID
- 90 µg /kg Loncastuximab Tesirine (for first 2 cycles followed by 75µg/kg for subsequent cycles) + Acalabrutinib 100 mg BID
The DLT evaluation period is two cycles (42 days).
Loncastuximab Tesirine will be given as an IV infusion, each cycle is a 21 day cycle, with Loncastuximab Tesirine given day 1 of each cycle.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Pamela M Hardwick
- Phone Number: 2059755387
- Email: pamdixon@uab.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Mayur Narkhede
- Phone Number: 205-934-4228
- Email: msnarkhede@uabmc.edu
-
Contact:
- Pam Dixon
- Phone Number: (205) 975-5387
- Email: pamdixon@uab.edu
-
Principal Investigator:
- Mayur S Narkhede, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Inclusion Criteria For all patients
Diagnosis of CLL according to the IwCLL criteria or SLL according to the World Health Organization (WHO) criteria. This includes previous documentation of:
- Biopsy-proven small lymphocytic lymphoma OR
- Diagnosis of CLL according to the IWCLL criteria as evidenced by Peripheral blood lymphocyte count of greater than 5 x109/L .
- Immunophenotype consistent with CLL defined as the predominant population of lymphocytes share both B cell antigens (CD19, CD20 (typically dim expression), or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc).
- On therapy with acalabrutinib for a minimum of 3 months without evidence of progression as per IWCLL 2018 criteria.
- Relapsed or Refractory CLL who have received at least one prior therapy before initiation of acalabrutinib
- Presence of measurable residual disease in the peripheral blood or bone marrow aspirate by NGS based clonoseq test.
Adequate organ function as defined below unless attributed to disease involvement:
- Liver function (bilirubin ≤ 1.5 × ULN, AST and/or ALT <3 x ULN). Patients with Gilbert Disease are permitted irrespective of bilirubin values.
- Kidney function (crcl > 30ml/min using Cockroft-Gault, based on actual weight).
- ANC ≥ 1,000/µL, Hgb > 8, Platelet Count ≥ 50,000/ µL. Use of G-CSF is not permitted for up to 7 days prior to enrollment.
Exclusion Criteria:
Exclusion Criteria For all patients
- Current evidence of central nervous system involvement.
- Unable to generate clonoseq ID specimen for measurable residual disease tracking.
- Completion of an autologous hematopoietic stem cell transplantation within 3 months prior to first dose of study drug.
- Prior allogeneic stem cell transplant within 6 months. The patient should not have any active Graft vs. Host disease (GVH) or should be on immune suppressive agents.
- Completion of treatment with any radiotherapy, chemotherapy, antibody, immunoconjugates and/or another investigational drug ≤4 weeks (or 5 half-lives of the drug, whichever is shorter) prior to the first dose of study drug. Patients may be enrolled after a minimum of 2 weeks of radiation if radiation was for palliative intent.
- Progression of disease on BTK inhibitor.
- Unable to tolerate full dose of acalabrutinib at 100 mg twice a day.
- Inability to swallow and retain oral medications.
- Pregnant women are excluded from this study.
Any active, concurrent, significant illness or disease (other underlying lymphoma) or clinically significant findings including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the patient from participation in the study such as:
- active infection requiring systemic therapy ≤10 days before the first dose of study drug
- unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association [NYHA] II, III, IV;), myocardial infarction ≤6 months prior to first study drug, uncontrolled cardiac arrhythmia e.g., atrial fibrillation/flutter, cerebrovascular accidents ≤6 months before first dose of study drug
- Significant (as defined by study doctor) pulmonary disease or disorder
- any severe or uncontrolled other disease or condition which might increase the risk associated with study participation
- Vaccination with live, attenuated vaccines within 28 days prior to the first dose of study medication.
- Receiving systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents). The use of inhaled corticosteroids is permitted.
- Corticosteroids ≥ 10 mg of prednisone within the last 7 days.
- Has had a solid organ transplant within the last 3 years. Note: Patients who have had a Solid organ transplant >3 years ago are eligible if there are no signs/symptoms of graft versus host disease (GvHD) and off immunosuppressive medications as per above.
- Known history of hypersensitivity to loncastuximab tesirine
- Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
- Breastfeeding or pregnant
Any other malignancy known to be active, with the exception of
- Cervical carcinoma of Stage 1A (1A1,1A2) and 1B (1B1,1B2,1B3)
- Non-invasive basal cell or squamous cell skin carcinoma
- Non-invasive, superficial bladder cancer
- Prostate cancer with a current PSA level < 0.1 ng/mL
- Any curable or localized cancer with a CR of > 2 years' duration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Level 1:
45 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
|
Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
|
Experimental: Dose Level 2
60 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
|
Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
|
Experimental: Dose Level 3
75 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
|
Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
|
Experimental: Dose level 4:
90 µg /kg Loncastuximab Tesirine (for first 2 cycles followed by 75µg/kg for subsequent 10 cycles) + Acalabrutinib 100 mg BID for a total of 12 cycles.
|
Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Objective
Time Frame: 12 months
|
Recommended phase 2 dose of loncastuximab tesirine in combination with acalabrutinib
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Objective 1
Time Frame: 6 months
|
undetectable measurable residual disease rate (uMRD) at 6 months of combination therapy in peripheral blood by NGS based clonoseq test
|
6 months
|
Secondary Objective 2
Time Frame: 12 months
|
Undetectable measurable residual disease rate (uMRD) at 12 months of combination therapy by NGS based clonoseq test.
|
12 months
|
Secondary Objective 3
Time Frame: 12 months
|
Best Overall response rate (ORR = CR+CRi+PR) of loncastuximab tesirine in combination with acalabrutinib
|
12 months
|
Secondary Objective 4
Time Frame: 12 months
|
Complete response rate (CRR= CR + CRi) of loncastuximab tesirine in combination with acalabrutinib in achieving a complete response.
|
12 months
|
Secondary Objective 5
Time Frame: 12 months
|
Progression free survival (PFS) at 12 months after completion of all treatment.
|
12 months
|
Secondary Objective 6
Time Frame: 12 months
|
Incidence of adverse events (AE) of loncastuximab tesirine in combination with acalabrutinib.
|
12 months
|
Secondary Objective 7
Time Frame: 12 months
|
Duration of response (DOR) of loncastuximab tesirine in combination with acalabrutinib
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mayur Narkhede, M.D., University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Leukemia, B-Cell
- Chronic Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Acalabrutinib
- Loncastuximab tesirine
Other Study ID Numbers
- IRB-300009213
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteWithdrawnRefractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Celgene CorporationTerminatedChronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
Clinical Trials on Loncastuximab Tesirine and Acalabrutinib
-
University of MiamiADC Therapeutics S.A.RecruitingMarginal Zone LymphomaUnited States
-
Barbara Ann Karmanos Cancer InstituteWithdrawnRelapsed Diffuse Large B-cell LymphomaUnited States
-
ADC Therapeutics S.A.No longer availableRelapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
-
M.D. Anderson Cancer CenterRecruitingLymphoma | Large B-cell LymphomaUnited States
-
ADC Therapeutics S.A.RecruitingDiffuse Large B-Cell Lymphoma | High-grade B-cell LymphomaTaiwan, Korea, Republic of, United States, Brazil
-
ADC Therapeutics S.A.CompletedDiffuse Large B-cell LymphomaSpain, United States, Italy, Puerto Rico
-
ADC Therapeutics S.A.TerminatedDiffuse Large B-Cell Lymphoma | Mantle Cell LymphomaUnited States, Spain, United Kingdom, France, Italy, Belgium
-
University of WashingtonRecruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Refractory Mantle Cell Lymphoma | Recurrent Follicular... and other conditionsUnited States
-
ADC Therapeutics S.A.TerminatedFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell LymphomaSpain, United States
-
ADC Therapeutics S.A.RecruitingB-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin LymphomaUnited States, Spain, Italy, United Kingdom, Belgium, Czechia